Why?
1. APIs are becoming more and more
potent. According to an estimation by ISPE (Winter Conference Berlin 2002), by
2010 more than 85 % of all NCE will be classified potent (OEL < 10 µg/m³).
2. Health and safety authorities all around the world are putting more
focus on the protection of operators dealing with these substances. 3.
Suppliers of various hardware components have developed a huge variety of
containment solutions, making it difficult to decide on the optimal solution,
even for experienced people.
A NEW article from Dr. Harald
Stahl
Dr Harald Stahl is a Senior Pharmaceutical Technologist with
GEA Pharma Systems. He is an executive member of the ISPE Containment Community
of Practice (CCOP), and has published more than 20 papers on various aspects of
solid dosage form production, of which several have a special focus on
containment aspects. Dr Stahl holds a Diploma in Physics and a PhD in Chemical
Engineering.
To read the complete article, click on this link
Contact:
Dr Harald Stahl
Senior pharmaceutical technologist
at
GEA Pharma Systems
Tel. +49 6349 927 706
Email: harald.stahl@geagroup.com